{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:30:36Z","timestamp":1778243436155,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1136\/annrheumdis-2021-220363","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T17:32:05Z","timestamp":1629307925000},"page":"1568-1574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity"],"prefix":"10.1016","volume":"80","clinical-trial-number":[{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3136-0722","authenticated-orcid":false,"given":"Diogo","family":"Jesus","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-5967","authenticated-orcid":false,"given":"Maddalena","family":"Larosa","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Henriques","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Matos","sequence":"additional","affiliation":[]},{"given":"Margherita","family":"Zen","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Tom\u00e9","sequence":"additional","affiliation":[]},{"given":"Valter","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Costa","sequence":"additional","affiliation":[]},{"given":"V\u00e9ronique","family":"Le Guern","sequence":"additional","affiliation":[]},{"given":"Luca","family":"Iaccarino","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-9021","authenticated-orcid":false,"given":"Nathalie","family":"Costedoat-Chalumeau","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-4983","authenticated-orcid":false,"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds Sousa","family":"In\u00eas","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2021-220363_bib1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.autrev.2014.01.055","article-title":"Optimizing outcome in SLE: treating-to-target and definition of treatment goals","volume":"13","author":"Doria","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1136\/annrheumdis-2021-220363_bib2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international Task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","article-title":"Prolonged remission in Caucasian patients with SLE: prevalence and outcomes","volume":"74","author":"Zen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/annrheumdis-2016-210154","article-title":"The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients","volume":"76","author":"Zen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib5","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2016-210382","article-title":"Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus","volume":"76","author":"Mok","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"Update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"2019","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international Task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2021-220363_bib9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0961203319836717","article-title":"Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients","volume":"28","author":"Jesus","year":"2019","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2021-220363_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/annrheumdis-2021-220363_bib11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/acr.23109","article-title":"Defining low disease activity in systemic lupus erythematosus","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2021-220363_bib12","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib13","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1136\/annrheumdis-2017-211814","article-title":"Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American lupus cohort (GLADEL)","volume":"76","author":"Ugarte-Gil","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib14","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. development and initial validation of an updated version of the British Isles lupus assessment group's disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2021-220363_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/annrheumdis-2018-214502","article-title":"Derivation and validation of the SLE disease activity score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity","volume":"78","author":"Jesus","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib16","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1136\/annrheumdis-2019-215794","article-title":"Response to: 'SLE-DAS: ready for routine use' by Mathew et al","volume":"79","author":"Jesus","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib17","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1136\/annrheumdis-2019-216110","article-title":"Response to: 'Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in a Latin American population' by Rodr\u00edguez-Gonz\u00e1lez et al","volume":"79","author":"Jesus","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib18","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1136\/annrheumdis-2019-215430","article-title":"Response to: 'Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort', by Hassan et al","volume":"79","author":"Jesus","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2021-220363_bib20","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2021-220363_bib21","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2021-220363_bib22","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2021-220363_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.patcog.2019.02.023","article-title":"The impact of class imbalance in classification performance metrics based on the binary confusion matrix","volume":"91","author":"Luque","year":"2019","journal-title":"Pattern Recognit"},{"key":"10.1136\/annrheumdis-2021-220363_bib24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.aci.2018.08.003","article-title":"Classification assessment methods","volume":"17","author":"Tharwat","year":"2021","journal-title":"Appl Comput Inform"},{"key":"10.1136\/annrheumdis-2021-220363_bib25","first-page":"27","article-title":"Evaluation measures for models assessment over imbalanced data sets","volume":"3","author":"Bekkar","year":"2013","journal-title":"J Info Engineer App"},{"key":"10.1136\/annrheumdis-2021-220363_bib26","author":"Thiele"},{"key":"10.1136\/annrheumdis-2021-220363_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jclinepi.2008.07.009","article-title":"Using the entire cohort in the receiver operating characteristic analysis maximizes precision of the minimal important difference","volume":"62","author":"Turner","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1136\/annrheumdis-2021-220363_bib28","series-title":"Applied logistic regression","author":"Hosmer","year":"2000"},{"key":"10.1136\/annrheumdis-2021-220363_bib29","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1093\/rheumatology\/keaa383","article-title":"Use of physician global assessment in systemic lupus erythematosus: a systematic review of its psychometric properties","volume":"59","author":"Chessa","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2021-220363_bib30","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League against Rheumatism\/American College of rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2019.06.007","article-title":"Suspected systemic rheumatic diseases in patients presenting with cytopenias","volume":"33","author":"Nikolopoulos","year":"2019","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2021-220363_bib32","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR Task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib33","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-220363_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000157","article-title":"Independent association of glucocorticoids with damage accrual in SLE","volume":"3","author":"Apostolopoulos","year":"2016","journal-title":"Lupus Sci Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724204416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724204416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2021-220363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:22:53Z","timestamp":1737249773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724204416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0003496724204416"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2021-220363","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2021-220363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 \u00a9 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}